BIOTECHNOLOGY Archives - Page 24 Of 345 - Medical Device News Magazine

Epredia Announces the U.S. Launch of SlideMate Laser | Provides State-of-the-Art Precision Slide Printing for Pathology Laboratories

Epredia has designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability.

January 11, 2024

Leading Pharma Adopts Veeva Vault Validation Management for Digital Validation Execution and Improved Efficiency

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., a global biotech company, is using Veeva Vault Validation Management to streamline and accelerate their validation process. By adopting a validation solution with built-in best practices, the company can execute digital validation while centralizing data and improving visibility.

January 11, 2024

Thermo Fisher Scientific Launches PangenomiX Array to Support Population-Scale Disease Studies and Pharmacogenomics Research

The PangenomiX Array is currently the only research solution that combines four assays in one test: SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood and HLA typing. The high-throughput array is designed to advance disease risk and detection research, population-scale disease research programs, ancestry and wellness testing, drug efficacy testing, and drug development research.

January 4, 2024

HORIBA Medical Launches Next Generation HELO Fully Automated Modular Hematology Solution

HELO 2.0 offers a highly flexible and efficient modular hematology solution that is fully scalable with many possible configurations for mid to large-scale laboratories.

January 4, 2024

Amgen Provides Regulatory Update on the Status of Lumakras® (Sotorasib)

This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer. The FDA also issued a new postmarketing requirement for an additional confirmatory study to support full approval that will be completed no later than February 2028.

December 26, 2023

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

The Australian patent Office granted patent No. 2019252987 titled ‘Cell-Type Specific Exosomes and Use Thereof’ for an isolated Exosomes population derived from MSC-NTF cells as well as a pharmaceutical composition for the treatment of neurodegenerative diseases.